Wednesday, October 30, 2019 2:42:19 PM
Since I only began building my cannabis portfolio during September, and have been scaling in, I have a few winners even on these down crappie days. By sheer luck I avoided the great cannabis PPS recession.
The whole industry is being revalued right now. It's definitely been going on since the Spring when the euphoria wore off after legalization a year ago.
By the time the SAFE Banking Act passes the Senate and is signed into law by the President, the great cannabis recession is going to play out.
In the meantime Health Canada is moving too slow to open outlets. They are choking the distribution channel. But more will open each year helping to improve all cannabis companies financial health. Some won't last though. The weakest will wither on the vine and die.
Too much investment and carrying costs went into building out too much grow capacity. Supply and purchase-able demand needs to be rebalanced. The giant cannabis growers turned the flower into a commodity. Most cannabis business plans never figured their selling price per gram and gross margins would be as low as they are right now.
Companies diluted the heck out of shareholders to raise equity capital to do much of that expansion.
Look to invest in companies that find ways other than through dilution to raise expansion funds.
If they are raising equity capital to pay the rent, maybe you should dump those even if you love the company.
In America, the MSO's have to operate inefficiently by duplicating in every state they enter the seed-to-sale formula. Imagine if GM needed 50 factories in every state to build each of its models. How crazy would that be?
Announced M&A's are being revalued as I type. Other M&A's are being cancelled.
Consolidation and bankruptcies are inevitable. The shake out is already beginning. It will reach a bottom. Valuations are becoming much more reasonable.
Private and public equity raises are going to start drying up for companies that can't show a path towards profitability.
The companies with the strongest balance sheets, growing revenues and best of category products are going to be the survivors.
Institutions are going to find the companies in the best financial health, with the best potential for steady revenue and bottom line growth, and then take large positions in them.
Recent OGI News
- Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year • Business Wire • 04/08/2024 10:00:00 AM
- Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales • Business Wire • 04/03/2024 12:06:00 PM
- Organigram Successfully Closes Previously Announced Underwritten Public Offering • Business Wire • 04/02/2024 12:51:00 PM
- Organigram Announces Pricing of Overnight Marketed Public Offering • Business Wire • 03/27/2024 12:56:00 PM
- Organigram Announces Launch of Overnight Marketed Public Offering • Business Wire • 03/26/2024 11:06:00 PM
- Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment • Business Wire • 03/26/2024 05:36:00 PM
- Organigram Receives Health Canada’s Final Redetermination on Jolts • Business Wire • 03/22/2024 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 03:42:13 PM
- Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty • Business Wire • 02/28/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 12:23:18 PM
- Organigram Reports First Quarter Fiscal 2024 Results • Business Wire • 02/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:25:53 PM
- Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024 • Business Wire • 02/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:36:42 PM
- Organigram Completes First Shipment to Germany, Extending its International Reach • Business Wire • 01/31/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:23:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 10:30:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 02:23:37 PM
- Organigram Announces the First Tranche Closing from BAT Investment • Business Wire • 01/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 12:38:06 PM
- Organigram Announces Appointment of Karina Gehring to Board of Directors • Business Wire • 01/19/2024 11:00:00 AM
- Organigram Announces Results of Annual and Special Meeting, including Shareholder Approval of C$124.6 Million Investment from BAT • Business Wire • 01/19/2024 01:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 12:25:46 PM
- Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting • Business Wire • 12/29/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 09:50:29 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM